Cabot (NYSE:CBT) Rating Lowered to “Hold” at StockNews.com

StockNews.com lowered shares of Cabot (NYSE:CBT) from a buy rating to a hold rating in a research note released on Wednesday morning.

Other equities analysts also recently issued research reports about the stock. UBS Group reduced their price target on shares of Cabot from $93.00 to $83.00 and set a “neutral” rating for the company in a report on Monday, April 7th. JPMorgan Chase & Co. reduced their target price on shares of Cabot from $105.00 to $85.00 and set an “underweight” rating for the company in a research note on Friday, February 21st. Finally, Mizuho decreased their target price on shares of Cabot from $122.00 to $110.00 and set an “outperform” rating for the company in a research report on Tuesday, January 7th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $93.25.

Cabot Price Performance

Shares of NYSE:CBT opened at $79.60 on Wednesday. The company has a market cap of $4.32 billion, a PE ratio of 10.57, a P/E/G ratio of 0.74 and a beta of 1.04. Cabot has a fifty-two week low of $73.63 and a fifty-two week high of $117.46. The firm has a 50-day simple moving average of $83.53 and a 200 day simple moving average of $95.92. The company has a quick ratio of 1.29, a current ratio of 2.00 and a debt-to-equity ratio of 0.72.

Cabot (NYSE:CBT) last posted its earnings results on Monday, February 3rd. The specialty chemicals company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.74 by $0.02. Cabot had a return on equity of 26.79% and a net margin of 10.60%. On average, sell-side analysts anticipate that Cabot will post 7.57 EPS for the current year.

Institutional Trading of Cabot

Institutional investors have recently made changes to their positions in the stock. R Squared Ltd acquired a new position in shares of Cabot during the fourth quarter valued at approximately $26,000. EverSource Wealth Advisors LLC boosted its stake in Cabot by 37.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 808 shares of the specialty chemicals company’s stock valued at $74,000 after purchasing an additional 219 shares in the last quarter. Curat Global LLC acquired a new position in shares of Cabot during the 1st quarter valued at $83,000. GAMMA Investing LLC increased its position in shares of Cabot by 10.7% during the 4th quarter. GAMMA Investing LLC now owns 1,348 shares of the specialty chemicals company’s stock valued at $123,000 after purchasing an additional 130 shares during the period. Finally, Manchester Capital Management LLC raised its stake in shares of Cabot by 1,685.1% in the 4th quarter. Manchester Capital Management LLC now owns 1,678 shares of the specialty chemicals company’s stock worth $153,000 after buying an additional 1,584 shares in the last quarter. 93.18% of the stock is owned by institutional investors and hedge funds.

Cabot Company Profile

Cabot Corporation operates as a specialty chemicals and performance materials company. The company operates through two segments, Reinforcement Materials and Performance Chemicals. It offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.